Wilburn E. Reddick1, Junyu Guo1, Qing Ji1, John O. Glass1, Mary E. McCarville2, Najat C. Daw3
1Translational Imaging Research, St. Jude Children's Research Hospital, Memphis, TN, USA; 2Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA; 3Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
We evaluated feasibility of DCE-MRI to assess the effect of chemotherapy and bevacizumab on tumor in six children treated for osteosarcoma. Bevacizumab is given three days before the first cycle of chemotherapy (day-3) and on the first day of subsequent cycles. DCE-MRI was performed at baseline, day-2, day+1, day+5, week5, and week10 before definitive surgery. Ktrans and ve did not change substantially for the initial two time points, but kep increased after bevacizumab alone on day-2 and day+1 then decreased during chemotherapy on day+5. DCE-MRI assessment of tumor changes during neoadjuvant chemotherapy and bevacizumab shows promising results for further investigation.